4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-25-124516
Chief Scientific Officer acquired 35,389 shares (conversion)
- Chief Scientific Officer returned 35,389 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Reich Kristian Chief Scientific Officer | 2025-12-19 | Conversion | +35,389 | 35,389 | D: show line 1 in the form | ||
| Reich Kristian Chief Scientific Officer | 2025-12-19 | Returned to the company | −35,389 | 0 | D: show line 2 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Reich Kristian Chief Scientific Officer | 2025-12-19 | Conversion · Common shares, par value CHF 0.10 per share, of MoonLake AG | −1,052 | 0 | D: show line 3 in the form |
Loading xslF345X05/ownership.xml…